Biotech investors are searching for the next blockbuster medicine, while pharmaceutical giants are searching for something equally valuable: a replacement for the blockbusters they already own. With patent expirations threatening established revenue streams, promising drug developers are attracting attention from both Wall Street and potential buyers. Advances in obesity, oncology, and other treatment areas are adding to the excitement. The challenge is finding companies whose science, finances, and valuations can withstand scrutiny after the investor presentation ends.
Big Pharma’s Patent Clock Is Getting Louder
For major pharmaceutical companies, patent protection is a powerful advantage with an inconvenient feature: an expiration date. When cheaper competitors enter the market, even a dependable bestseller can become a much less dependable source of growth. Replenishing the pipeline becomes increasingly urgent as that deadline approaches.
That pressure was already showing up in deal activity early in 2026. In a May 1 report, Reuters cited Dealogic figures showing that first-quarter biotech deal value reached $84 billion, compared with $44.4 billion a year earlier. The same report cited a William Blair estimate that more than $300 billion in pharmaceutical revenue faced potential losses of exclusivity over the following five years. That is a considerable amount of business to replace before the patents stop doing the heavy lifting.
By July, the acquisition pace had accelerated further. The Financial Times reported on July 21 that 37 biotech acquisitions worth at least $1 billion had been announced that year, surpassing the previous full-year record of 35, according to Stifel. Separately, LSEG data cited in the report placed biotech deal value at $216 billion, against $118 billion during the corresponding period in 2025.
The investment appeal is understandable. A smaller developer with a differentiated medicine could offer a larger buyer a valuable source of future growth. Still, a busy acquisition market does not turn every clinical-stage company into the next bidding war.
Buyers Prefer Pipelines With a Shorter Route to Revenue
The contents of a deal matter more than its headline price. The Financial Times described growing buyer interest in companies with revenue-generating medicines or treatments approaching launch. For drugmakers facing patent expirations, the commercial timetable matters almost as much as the science.
A medicine that could reach patients soon offers a different proposition from one that still needs years of trials, regulatory reviews, and financing. “Enormous long-term potential” is an easier pitch when the buyer’s existing revenue has time to wait.
Earlier-stage developers can still offer substantial opportunities, but investors need to examine what must happen before their medicines become viable products. Differentiated science, credible development plans, and sufficient funding all matter. A takeover might reward shareholders handsomely, but the company should have a workable future if prospective buyers keep their wallets closed.
The arithmetic also deserves attention from the buyer’s side. Our analysis of Biogen examines how pipeline acquisitions can strengthen a growth outlook while adding earnings charges and execution risk. Filling a pipeline gap can be strategically sensible. Whether the purchase creates shareholder value also depends on the price paid and what happens afterward.
Weight-Loss Drugs Carry Some Very Heavy Expectations
Obesity remains one of biotechnology’s most closely watched markets. A September 30 Reuters overview cited analyst expectations that annual weight-loss drug sales could approach $100 billion over the next decade. The treatments target smaller waistlines; the revenue forecasts are considerably less restrained.
Developers are competing through oral medicines, less frequent injections, and approaches designed to preserve lean mass. These differences could influence which treatments patients prefer, physicians prescribe, and payers cover. Their commercial value, however, depends on convincing clinical evidence and practical benefits.
Convenience alone does not settle the competition. Reimbursement, affordability, manufacturing capacity, and access will help determine how much of the projected demand becomes actual revenue. A large addressable market looks excellent in a presentation. An insurer still wants a reason to pay.
Commercialization also brings challenges beyond competing medicines. An August 28 Financial Times report examined counterfeit weight-loss treatments in the UK, noting that Novo Nordisk had secured an expanded website-blocking order while Eli Lilly was disrupting online sellers of unlicensed products.
Those efforts highlight the importance of trusted distribution and product integrity. Strong demand creates an opportunity for legitimate developers, but it also attracts sellers whose enthusiasm for the market exceeds their interest in regulatory approval.
A Promising Pipeline Still Needs Cash Behind It
Across biotechnology, compelling science needs financial staying power. Profitable companies can be assessed through earnings, cash flow, and the durability of their existing products. Clinical-stage developers require closer attention to cash reserves, spending, and the financing needed to reach meaningful milestones.
A company may have an attractive drug candidate and still leave shareholders facing repeated dilution before it reaches the market. Investors should therefore examine both the next clinical catalyst and the cost of getting there. The laboratory can produce encouraging results; it cannot print working capital.
Our earlier coverage of Viking Therapeutics connects progress in its obesity pipeline with the cash available to fund further development, showing why clinical prospects and financial resources belong in the same assessment.
Billionaire ownership can help identify companies drawing attention from experienced investors. It cannot guarantee a successful trial, secure regulatory approval, or make an expensive stock reasonably priced. Even the most impressive shareholder register gets no special treatment from a clinical endpoint.
The stronger investment candidates combine differentiated science, sufficient funding, and a valuation that allows for uncertainty. A successful trial or acquisition could deliver substantial upside. The investment case should also explain how the company moves forward when development takes longer, financing becomes more expensive, or the anticipated buyer never calls.
CHECK THIS OUT: 10 Best Biotech Stocks Under $10 to Buy Now and Top 6 Small-Cap Healthcare Stocks to Buy Right Now.
Our Methodology
To identify the 10 best biotech stocks to buy according to billionaires, we reviewed financial media sources and stock screeners for U.S.-listed biotechnology companies, selected the 10 with the most bullish billionaire positions in our Q2 2026 holdings database, and ranked them in ascending order by the number of billionaire holders.
CLICK HERE TO READ THE FULL ARTICLE: 10 Best Biotech Stocks to Buy According to Billionaires
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)
Number of Hedge Fund Holders — 45
Number of Billionaire Holders — 18
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) has moved an important part of its investment story from regulatory anticipation to commercial execution.
On September 21, the European Commission approved Ubeslo, containing obicetrapib, and Evlarco, a fixed-dose combination of obicetrapib and ezetimibe. The authorizations marked the first global approvals of obicetrapib and cover specified patients with primary hypercholesterolemia or mixed dyslipidemia.
The supporting Phase 3 program demonstrated substantial LDL-cholesterol reductions. According to the approval announcement, reductions versus placebo reached up to 40% with monotherapy and approximately 50% with the combination. These findings establish a cholesterol-lowering proposition, while dedicated cardiovascular-outcomes evidence remains another important part of the program.
CEO Michael Davidson described the authorization as “the first regulatory approval of obicetrapib globally.”
The commercial arrangement gives shareholders a specific revenue mechanism to assess. Its European partner holds regional commercialization rights, while the company is entitled to tiered royalties ranging from the low double digits to the mid-twenties on applicable net sales. Regulatory approvals also triggered milestone payments in the mid-teens of millions of euros.
Approval, however, does not fill prescriptions by itself. Launch execution, reimbursement decisions, physician adoption, and patient persistence will determine the pace of royalty growth.
The company reported $678.3 million in cash, cash equivalents, and marketable securities at June 30. Its August update also scheduled an interim PREVAIL cardiovascular-outcomes analysis for the fourth quarter, with results expected in the first quarter of 2027.
For investors assessing cardiovascular biotech stocks, the opportunity now combines an approved European product franchise with further clinical evidence that could influence its longer-term positioning.
Ranking rationale: NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) ranks ninth with 18 billionaire holders. European approvals and contractual royalty rights strengthen its investment case, while commercial uptake and cardiovascular-outcomes results remain important variables.
YOU MUST READ THIS: 10 Promising Small-Cap Biotech Stocks to Watch
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
